1. Home
  2. TRS vs NVCR Comparison

TRS vs NVCR Comparison

Compare TRS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriMas Corporation

TRS

TriMas Corporation

SELL

Current Price

$36.91

Market Cap

1.3B

Sector

Industrials

ML Signal

SELL

Logo NovoCure Limited

NVCR

NovoCure Limited

SELL

Current Price

$11.16

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TRS
NVCR
Founded
1986
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Specialties
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
TRS
NVCR
Price
$36.91
$11.16
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
★ $45.00
$26.14
AVG Volume (30 Days)
404.4K
★ 1.7M
Earning Date
10-29-2026
10-29-2026
Dividend Yield
★ 0.44%
N/A
EPS Growth
N/A
★ 21.79
EPS
★ 22.64
N/A
Revenue
$645,720,000.00
★ $655,353,000.00
Revenue This Year
$5.16
$12.95
Revenue Next Year
$1.55
$9.33
P/E Ratio
$1.61
★ N/A
Revenue Growth
N/A
★ 8.28
52 Week Low
$31.67
$9.82
52 Week High
$45.43
$21.45

Technical Indicators

Market Signals
Indicator
TRS
NVCR
Relative Strength Index (RSI) 38.45 30.84
Support Level $35.40 $10.14
Resistance Level $40.10 $18.43
Average True Range (ATR) 1.37 0.80
MACD -0.25 -0.17
Stochastic Oscillator 18.40 4.97

Price Performance

Historical Comparison
TRS
NVCR

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: